#pharmaindustry
GLP-1 Weight Loss Drugs Lift Pharma Profits, But Deloitte Warns of Bubble Risk
GLP-1 Drugs Drive Pharma Growth GLP-1 weight loss drugs are powering a sharp rebound in pharma R&D returns, but analysts warn the boom may be creating a risky “bubble effect” across the sector. According to Deloitte’s latest pharma innovation analysis, R&D returns among the world’s top 20 drugmakers have climbed to 7%, driven largely by obesity and diabetes treatments such as GLP-1 drugs. Obesity Drugs Overtake Oncology
GLP-1 Weight Loss Drugs Lift Pharma Profits, But Deloitte Warns of Bubble Risk
GLP-1 Drugs Drive Pharma Growth GLP-1 weight loss drugs are powering a sharp rebound in pharma R&D returns, but analysts warn the boom may be creating a risky “bubble effect” across the sector. According to Deloitte’s latest pharma innovation analysis, R&D returns among the world’s top 20 drugmakers have climbed to 7%, driven largely by obesity and diabetes treatments such as GLP-1 drugs. Obesity Drugs Overtake Oncology
New pancreatic cancer drug shows major survival gains in Phase 3 study
REDWOOD CITY, California — Revolution Medicines announced positive results from a late-stage clinical trial evaluating its experimental drug daraxonrasib, showing a significant survival benefit for patients with advanced pancreatic cancer who had previously undergone treatment. According to the company, patients receiving the once-daily oral therapy lived a median of 13.2 months, compar
New pancreatic cancer drug shows major survival gains in Phase 3 study
REDWOOD CITY, California — Revolution Medicines announced positive results from a late-stage clinical trial evaluating its experimental drug daraxonrasib, showing a significant survival benefit for patients with advanced pancreatic cancer who had previously undergone treatment. According to the company, patients receiving the once-daily oral therapy lived a median of 13.2 months, compar
Trump drug pricing deals seen as limited relief for most U.S. patients
President Donald Trump’s recently announced agreements with pharmaceutical companies are expected to have a limited effect on what most Americans pay for prescription drugs, according to health policy experts who say the scope and structure of the deals leave many patients unaffected. Since Sept. 30, the Trump administration has reached agreements with 14 drugmakers in exchange for relie
Trump drug pricing deals seen as limited relief for most U.S. patients
President Donald Trump’s recently announced agreements with pharmaceutical companies are expected to have a limited effect on what most Americans pay for prescription drugs, according to health policy experts who say the scope and structure of the deals leave many patients unaffected. Since Sept. 30, the Trump administration has reached agreements with 14 drugmakers in exchange for relie









